International: +1-347-960-6455
Diphtheria Therapeutics - Pipeline Analysis 2018

Diphtheria Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10059 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Infectious
Select License Type

Diphtheria is an infectious and vaccine preventable disease caused by Corynebacterium diphtheriae. It is generally characterized by upper respiratory tract infection, and the most common sites for this disease are pharynx and tonsils. Some of the symptoms include fever, sore throat, swollen glands, and weakness. Corynebacterium diphtheriae is a gram-positive bacterium that carries a gene for diphtheria toxin. Most of the strains of the bacterium require pantothenic acid and nicotinic acid for their growth. According to the morphology, bacterium is classified into three biotypes; gravis, mitis, and intermedius.

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.